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The Journal of Immunology
Soluble CD83 Inhibits T Cell Activation by Binding to the
TLR4/MD-2 Complex on CD14+ Monocytes
Joe M. Horvatinovich,*,1 Elizabeth W. Grogan,*,1 Marcus Norris,*
Alexander Steinkasserer,† Henrique Lemos,‡ Andrew L. Mellor,‡ Irina Y. Tcherepanova,*
Charles A. Nicolette,* and Mark A. DeBenedette*
The transmembrane protein CD83, expressed on APCs, B cells, and T cells, can be expressed as a soluble form generated by
alternative splice variants and/or by shedding. Soluble CD83 (sCD83) was shown to be involved in negatively regulating the
immune response. sCD83 inhibits T cell proliferation in vitro, supports allograft survival in vivo, prevents corneal transplant
rejection, and attenuates the progression and severity of autoimmune diseases and experimental colitis. Although sCD83 binds to
human PBMCs, the specific molecules that bind sCD83 have not been identified. In this article, we identify myeloid differentiation
factor-2 (MD-2), the coreceptor within the TLR4/MD-2 receptor complex, as the high-affinity sCD83 binding partner. TLR4/MD-2
mediates proinflammatory signal delivery following recognition of bacterial LPSs. However, altering TLR4 signaling can atten-
uate the proinflammatory cascade, leading to LPS tolerance. Our data show that binding of sCD83 to MD-2 alters this signaling
cascade by rapidly degrading IL-1R–associated kinase-1, leading to induction of the anti-inflammatory mediators IDO, IL-10, and
PGE2 in a COX-2–dependent manner. sCD83 inhibited T cell proliferation, blocked IL-2 secretion, and rendered T cells unre-
sponsive to further downstream differentiation signals mediated by IL-2. Therefore, we propose the tolerogenic mechanism of
action of sCD83 to be dependent on initial interaction with APCs, altering early cytokine signal pathways and leading to T cell
unresponsiveness. The Journal of Immunology, 2017, 198: 2286–2301.
H
uman CD83, identified as a 45-kDa type 1 membrane
glycoprotein of the Ig superfamily of receptors, is expressed
as a membrane-bound form and a soluble form (1, 2). The
transmembrane form of CD83 is expressed on mature dendritic
cells (DCs), B cells, macrophages, activated T cells and T regulatory
cells, and thymic epithelial cells (3, 4). The expression on DCs is
involved in the activation of T cell–mediated immune responses
(5–8); however, a soluble form of CD83, generated by splice
variants or by shedding, inhibits T cell proliferation (9). Soluble
CD83 (sCD83) released from tumor cells blocks CD4+ and CD8+
T cell proliferation (10). Additional studies revealed that sCD83 is
present in elevated concentrations in a number of hematological
malignancies, whereby higher sCD83 plasma levels correlated with
shorter treatment-free survival of these patients (11, 12). Released
sCD83 from mature DCs infected with CMV leads to inhibition of
T cell proliferation (13), and neonatal DC infection with either Gram-
negative or -positive bacteria releases sCD83, resulting in suppression
of allergic responses (14). These observations prompted several
groups to develop recombinant sCD83 proteins (15–17) to evaluate
the immunosuppressive activity of sCD83 for therapeutic use in
models of autoimmunity and transplantation. Preparations derived
from expression of the soluble portion of CD83 lacking the trans-
membrane domain used in in vivo models of murine and rat kidney
and heart allograft transplantation prevented organ transplant rejec-
tion (18–20). Moreover, sCD83 induced tolerance in skin allograft
transplants (21). In vitro evaluations showed that recombinant CD83
protein preparations inhibits T cell proliferation in vitro (22–24).
Moreover, recombinant sCD83 protein reduced the symptoms as-
sociated with models of experimental autoimmune encephalomy-
elitis (25) and murine experimental colitis (26) and, when applied
topically, prevented corneal graft rejection (27).
The underlying mechanism by which sCD83 mediates its reg-
ulatory properties is not clear. The extracellular domain of CD83 is
reported to bind to monocytes and DCs (24, 28), thus positioning
CD83 at the interface between innate and adaptive immunity. Pub-
lished reports suggest that the extracellular domain of CD83 fused
to Ig interacts with a 72-kDa glycosylated protein involved in cell
adhesion (29); however, this was not investigated further or con-
firmed by other investigators. Recently, it was indicated that CD83
may act in a homotypic way (30); however, the investigators failed to
demonstrate a clear biophysical interaction and, therefore, identifi-
cation of the sCD83 counterreceptor(s) remains elusive. Identifying
the biologically relevant cell surface receptor(s) for sCD83 would
greatly expand our understanding of how sCD83 mediates inhibition
of T cell activation, alleviates symptoms of autoimmune diseases,
and induces tolerance in the allograft transplant setting.
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In this study, we identified the cell surface binding partner for
sCD83 as myeloid differentiation factor-2 (MD-2), the coreceptor
associated with the TLR4 signaling complex. Furthermore, we
provide evidence that the expression of CD14 and CD44 on
monocytes is a necessary component of this unique complex of
receptors. The major role for TLR4 is recognition of pathogen-
associated molecular patterns, specifically LPS, from Gram-
negative bacteria, which serves as a strong inducer of innate
immunity (31–34). LPS signaling through TLR4 requires the
coreceptors CD14 and MD-2 because TLR4 does not bind LPS
directly (35–37). CD14 first binds LPS and transfers LPS to MD-2,
which lacks a transmembrane domain and does not transduce a
signal itself, but is responsible for dimerization of TLR4 mole-
cules once bound with LPS (31, 38). The crystal structure of the
TLR4/MD-2/LPS complex reveals that LPS binds to a hydro-
phobic pocket within MD-2 and alters the heterodimerized TLR4
complex (31, 35, 36). Ligand-induced dimerization results in the
recruitment of MyD88 and autophosphorylation of members of
the IL-1R–associated kinase (IRAK) family (IRAK-1 and IRAK-4),
which trigger NF-kB activation via TRAF6 (39–41). TLR4 and
IL-1 signaling through IRAK-1 drives proinflammatory cascades
relevant to tumorigenesis and serve as a target for antitumor
therapy (42). However, antagonist ligands can modulate these
adaptor proteins and modulate TLR4 signaling. Evidence for
TLR4/MD-2 delivering negative signals is not without precedent.
It is a characteristic of high-dose LPS tolerance, in which sus-
tained LPS signaling can lead to immune suppression (43–46).
Furthermore, antagonist derivatives of LPS were shown to dampen
the proinflammatory cascade associated with sepsis (38). To sup-
port our observation that sCD83 interacting with MD-2 alters the
TLR4 signaling complex, we provide further evidence that CD44R
expressing the v6 variant in the stem loop region expressed on
monocytes is an accessory receptor associated with the sCD83–
TLR4/MD-2 complex. The contribution of CD44v6 to TLR4/MD-2
signaling is not without precedent. During tissue injury, high m.w.
forms of hyaluronan bind to CD44, leading to alternative signaling
pathways through the TLR4 complex (44, 47, 48). Furthermore,
CD44v6 association with growth factor receptors can induce a
feedback loop of regulation mediated by COX-2–induced PGE2
(49). Taken together, these data provide a mechanism by which
highly potent proinflammatory signals can be turned off when no
longer required, such as during times of tissue repair and resolu-
tion of inflammation.
We report for the first time, to our knowledge, that sCD83 binds
directly to MD-2, the TLR4 coreceptor, with high affinity and
reveal a novel role for CD44v6 in sCD83 cell surface binding. The
mechanism of action driving sCD83 immune regulation is predi-
cated on sCD83 engagement of the TLR4/MD-2/CD14–CD44v6
complex, resulting in a lack of IRAK-1 protein expression.
One mechanistic point of LPS tolerance shown in promonocytic
THP-1 cells is the rapid degradation of IRAK-1 (50). Furthermore,
saponin-like compounds improved clinical outcomes in a mouse
model of colitis by blocking IRAK-1 activation and upregulating
IL-10 (51). Therefore, we propose that sustained loss of IRAK-1,
as a consequence of sCD83 signaling through TLR4, results in the
production of PGE2 and IL-10 and increased IDO activity, which
have the combined effect of inhibiting T cell activation. Moreover,
we present evidence that sCD83 addition during T cell activation
leads to blockade of T cell proliferation and alters cytokine-
secretion profiles, rendering T cells unresponsive to further down-
stream IL-2 expansion. Thus, sCD83 induces a form of IL-2 anergy.
Our data support the potential usefulness of sCD83 having thera-
peutic efficacy to treat autoimmune and inflammatory diseases, as
well as alleviate transplant rejection.
Materials and Methods
Preparation of recombinant sCD83 protein
The extracellular domain of human CD83 (20–145 aa) was PCR amplified,
and expression of sCD83 was induced in Escherichia coli and purified as
previously described (16, 24, 52). Briefly, sCD83 was purified using a
GSTrap 5-ml column (Amersham Pharmacia Biotech). The GST–sCD83–
containing fractions were loaded onto an anion exchange column, and
proteins were separated by three different linear salt gradients. The GST–
sCD83 fusion protein was incubated with thrombin to separate the sCD83
protein from GST and loaded onto glutathione Sepharose 4B columns. The
flow-through containing recombinant human sCD83 protein was collected.
A final gel-filtration separation was performed, loading the flow-through
onto a Superdex 75 column.
sCD83 binding to peripheral blood monocytes and DCs
Leukapheresis from healthy volunteers was provided by Key Biologics
(Memphis, TN). Mononuclear cells were isolated using Histopaque-1077
(Sigma-Aldrich), resuspended in FBS (Atlanta Biologicals) containing
10% DMSO (Sigma-Aldrich), and stored in liquid nitrogen. Thawed
PBMCs were washed twice in PBS (Cambrex) prior to use. To detect sCD83
bound to the surface of the cells, sCD83 protein (2 mg) was first incubated
with 1 3 106/100 ml of PBMCs resuspended in BD Stain Buffer (FBS; BD
Biosciences) for 15 min at room temperature. In some instances, sCD83
protein was incubated with recombinant MD-2 protein (1.5 mg) prior to
addition to cells for binding. Goat anti-human CD83 biotinylated poly-
clonal Ab (R&D Systems) was added to cells incubated with sCD83 and,
after washing, allophycocyanin–streptavidin (BD Biosciences) was added
to detect sCD83 protein bound to the cell surface of viable cells. For Ab-
blocking experiments, cells were incubated with the indicated purified Abs
to CD14 (clone M5E2, BD Biosciences; clone 61D3, eBioscience; clone
My4, Beckman Coulter), CD44s (clone 515, BD Biosciences; clone IM7,
eBioscience; clone 156-3c11, and clone 5F12, Invitrogen), CD44v6 (clone
VFF-7; eBioscience), TLR4/MD-2 (clone MTS510; eBioscience), or MD-2
(clone 984, eBioscience; clone 288307, R&D Systems) for 15 min at room
temperature prior to the addition of sCD83 protein and subsequent de-
tection of sCD83 bound to the surface of the cell, as described above.
Isotype-control IgG1 and IgG2a Abs were purchased from eBioscience.
Background staining was determined without the addition of sCD83 pro-
tein but in the presence of goat anti-human CD83 biotinylated polyclonal
Ab and allophycocyanin–streptavidin. Dead cells were gated using
7-aminoactinomycin D (BD Biosciences). All labeled samples were
acquired with an LSR II flow cytometer (BD Biosciences). In the binding-
competition experiments to detect direct binding of sCD83 to the surface
of cells, sCD83 protein was directly labeled using an Alexa Fluor 488
Protein Labeling Kit (Invitrogen), according to the manufacturer’s in-
structions. To detect surface-bound sCD83 protein and stain cells for
CD14, TLR4, MD-2, and CD44v6 expression, mouse anti-CD14 FITC
(BD Biosciences) was used to identify monocyte surface CD14, whereas
donkey anti-Mouse IgG PE-conjugated Ab (eBioscience) was used to in-
directly detect surface TLR4 or MD-2 after binding with sCD83. Detection
of sCD83 binding to DCs was performed using the indirect method, as
described, in conjunction with anti-CD303 FITC, anti-CD1c PE (Miltenyi
Biotec), anti-CD2 Qdot 605, anti CD14-Qdot 655 (Invitrogen), and anti-
PE–Cy7 CD123 (BD Biosciences) Abs. Cells were washed, centrifuged,
and resuspended in BD Stain Buffer (FBS) containing 7-aminoactinomycin
D and acquired with an LSR II flow cytometer. The gating strategy used to
detect surface-bound sCD83 protein in combination with conjugated Ab
staining is outlined in Supplemental Fig. 1. Sample analysis and positivity
based on probability binning were determined using FlowJo software v9.7
(TreeStar). The probability binning algorithm calculates a x2 value based
on differences in the number of events found in each corresponding bin
between the test and control samples.
Cell-free binding assay
sCD83 was prepared at 1 mg/ml in Coating Buffer (OptEIA Reagent Set B;
BD Biosciences) and incubated overnight at 4˚C. Plates were washed with
wash buffer (PBS with 0.05% Tween 20; OptEIA Reagent Set B) three
times using an ELx405 auto plate washer, and 300 ml of blocking buffer
(1% BSA in PBS) was added to each well. The plates were incubated for
2 h at 37˚C to block. After the blocking step, the plates were washed three
times with wash buffer. The proteins of interest (MD-2, CD14, MD-2 +
LPS, or LPS; R&D Systems, Sigma-Aldrich) were serially diluted in seven
tubes, and 100 ml of the diluted protein sample was transferred to the
appropriate wells on the capture plate. The plates were incubated for 1 h at
room temperature in the dark. Plates were washed, and goat anti-human
biotinylated CD83 detection Ab (R&D Systems) was added (100 ml
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per well) and incubated for 2 h at room temperature in the dark. The plates
were washed, and streptavidin-HRP was prepared at a 1:1000 dilution.
Streptavidin-HRP was added (100 ml per well), and the plates were in-
cubated for 1 h at room temperature in the dark. Plates were washed, the
development solution was prepared by combining equal parts of Substrate
A plus Substrate B (OptEIA Reagent Set B), and 100 ml of solution was
added to each well. The plates were allowed to develop for 1–10 min, and
the reaction was stopped by adding 50 ml of stop solution (OptEIA Re-
agent Set B) to each well. The plates were analyzed on a ELx800 universal
microplate reader at 450 nm.
Western blotting
Monocytes were isolated from PBMCs using negative selection (STEM-
CELL Technologies) and cultured in R-10 medium (10% FBS [Atlanta
Biologicals], RPMI 1640 supplemented with 10 mM HEPES [pH 7.4],
1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 2 mM sodium
glutamate, and 55 mM 2-ME [Invitrogen]) with GM-CSF overnight. sCD83
or LPS was added for the indicated times. Cells were lysed in ice-cold RIPA
buffer in the presence of a protease/phosphatase inhibitor mixture (Pierce
ECL Plus Western blotting Substrate). Bradford (BCA) protein assay
(Thermo Scientific) was performed to determine total protein concentra-
tions. A total of 4–5 mg of each lysate sample was run on each lane of a
Criterion 10–20% Tris-HCl gel. The gel was run at 200 V for 50 min. The
gel was transferred to a polyvinylidene difluoride membrane at 100 V for
75 min. The membrane was washed in TBS with 0.01% Tween 20 (TBS-T),
blocked in 5% nonfat milk in TBS-T for 1 h, and washed three times with
TBS-T. The washed membrane was incubated with primary Ab (1:1000;
IRAK1, IRAK2, IRAK-M, IRAK4, and TRAF6; all from Cell Signaling
Technology) in 3% BSA in TBS-T at 4˚C overnight. The membrane was
washed and then incubated with anti-rabbit HRP (1:2000) in blocking buffer
for 1 h. The blot was developed using an ECL Plus kit.
T cell stimulation assay
Human PBMCs from normal donors were thawed overnight in R-10 me-
dium. Cells were labeled with CFSE using the CellTrace CFSE Cell
Proliferation Kit, for flow cytometry (Life Technologies). CFSE-labeled
cells were incubated with various concentrations of sCD83 protein. To
stimulate proliferation of PBMCs, anti-human functional grade purified
CD3 and CD28 Abs (eBioscience) were added to the wells at a concen-
tration of 0.123 ng/ml, and cells were incubated for 6 d at 37˚C. On day 6,
cells were harvested and stained with Abs against CD3 (PECy7; BD Bio-
sciences), CD4 (Pacific Blue; BD Biosciences), and CD8 (PE–Texas Red–X
[ECD; Beckman Coulter]) for 15 min at room temperature. LIVE/DEAD
Fixable Aqua Dead Cell Stain (Life Technologies) was used as a viability
marker. Cells were washed twice with FACS stain buffer (with FBS; BD
Biosciences), stained with the Aqua Dead Cell Stain Kit for 15 min at room
temperature, and washed twice more with the FACS stain buffer. Fluores-
cence was measured on an LSR II, and a total of 100,000 events was collected
for each sample. Proliferation was measured by the distribution of CFSE in
each sample. Fluorescence was measured on an LSR II using FACSDiva
software (BD Biosciences). Data were analyzed with FlowJo software.
Detection of cytokine secretion
To evaluate cytokine secretion from stimulated PBMC cultures in response
to sCD83 treatment, the supernatant was collected after culture and ana-
lyzed for human cytokines using the Cytometric Bead Array kit (BD
Biosciences), according to the manufacturer’s instructions. Data were
analyzed using FCAP Array software (BD Biosciences). PGE2 concen-
trations were measured using a competitive ELISA kit (Thermo Fisher).
Detection of intracellular cytokine staining
Expression of IL-10, IFN-g, and TNF-a by T cells, B cells, and monocytes
was analyzed by intracellular cytokine staining. PBMCs were stimulated
with anti-CD3/anti-CD28 Abs and treated or not with sCD83 for 24 h.
GolgiPlug and GolgiStop (both from BD Biosciences) were added for the
final 18 h of stimulation. Twenty-four hours poststimulation, cells were
harvested, washed with FACS stain buffer, and stained for 15 min at room
temperature with the LIVE/DEAD Fixable Aqua Dead Cell Stain kit. Cells
were washed again, and labeled with anti-mouse CD3 allophycocyanin–
eFluor 780 (eBioscience), FITC anti-CD4 (BioLegend), BV786 anti-CD8
(BD Biosciences), BV605 anti-CD14 (BD Biosciences), and BV786 anti-
CD19 (BD Biosciences) Abs for 15 min at room temperature. Samples
were washed twice and fixed with BD Cytofix for 10 min at 4˚C. Cells
were washed and resuspended in FACS stain buffer and held overnight at
4˚C. The following day, tubes were washed with Perm/Wash buffer
(BD Biosciences). To set background gates, a single tube (blocked tube)
containing the blocking Abs (purified anti–IL-2 [BD Biosciences], purified
anti–IL-10 [eBioscience], purified anti–IFN-g [eBioscience], and purified
anti–TNF-a [BD Biosciences]) was added to the intracellular cytokine–
stained blocking tube for 10 min at room temperature. Anti–IL-2 PE (BD
Biosciences), anti–IL-10 PE-Cy7 (eBioscience), anti–IFN-g eFluor 450
(eBioscience), and anti–TNF-a Alexa Fluor 700 (BD Biosciences) Abs
were added to all tubes, and samples were incubated for 15 min at room
temperature. Cells were washed twice with Perm/Wash buffer and resus-
pended in FACS stain buffer for acquisition. Fluorescence was measured
on an LSR II using FACSDiva software, and data were analyzed with
FlowJo software. Background staining for each individual cytokine Ab was
determined by setting the gates on the nonstained cell population present in
the blocked tube (Supplemental Fig. 2).
Determination of IDO activity
IDO activity in PBMC cultures was assessed by detecting tryptophan and
the tryptophan catabolite kynurenine, which is generated by cells expressing
IDO. Kynurenine and tryptophan in culture media were measured by HPLC
after deproteination using a C18 reverse phase column, as described
(53, 54). Data are expressed as the ratio of kynurenine/tryptophan.
Statistics
Statistical analysis was performed using Microsoft Excel 2016 software
version (Santa Cruz, CA) and variances of mean values are presented as box-
and-whisker plots. Statistical comparisons of T cell subsets from different
donors were calculated using a paired t test. Spearman rho plots were
calculated for comparison of mean fluorescence intensity (MFI) values for
the cohort of six donors. The p values # 0.05 were considered statistically
significant.
Results
sCD83 binds to CD14+ monocytes expressing the TLR4
coreceptor MD-2
PBMCs were incubated with sCD83 protein, and cell surface
binding was detected on CD14+ monocytes and CD19+ B cells
(Fig. 1A). Forward and side scatter differentiated monocytes
from lymphocytes (Fig. 1Ai). There are no detectable CD14+/CD19+
double-positive B cells in the lymphocyte gate (Fig. 1Aii) or the
monocyte gate (Fig. 1Aiii). Within the monocyte gate, 98% of the
cells are CD14+, with no detectable CD19+ B cells present
(Fig. 1Aiii). sCD83 protein bound to the surface of 38% of the
CD19+ B cells (Fig. 1Aiv, open graphs) and 64% of the monocytes
(Fig. 1Av, open graphs). However, neither the monocytes nor
B cells show positive staining when the secondary anti-CD83 Ab
is added to cells in the absence of sCD83 protein; thus, neither cell
population expresses membrane-bound CD83 (Fig. 1Aiv, 1Av,
shaded graphs). The remaining cells in the lymphocyte gate do not
bind sCD83 protein (Fig. 1Avi). To show direct cell binding of
sCD83 protein, sCD83 protein was directly labeled with Alexa
Fluor 488 dye, and flow cytometry analysis revealed that fluorescent-
labeled protein and unlabeled sCD83 protein detected with the in-
direct biotinylated anti-CD83 Ab bound to the same cells, resulting
in 77.9% of the monocytes being double stained with both reagents
(Fig. 1B). To confirm specificity of sCD83 binding to monocytes, a
competition binding assay was performed. Direct binding of Alexa
Fluor 488–labeled sCD83 was inhibited when titered concentrations
of unconjugated sCD83 protein were preincubated with the cells,
demonstrating sCD83-specific binding to the cell surface of mono-
cytes (Fig. 1C). This prompted us to investigate the binding of
sCD83 to other APCs present in PBMCs. Mature DCs present in the
peripheral blood (55) were identified by the expression of CD123
and CD303 (plasmacytoid DCs) (Fig. 1D, top panel), and monocyte-
derived DCs were identified by the expression of CD1c and CD2
(Fig. 1E, top panel). sCD83 binding could be detected on a subset of
CD14+ DCs within the mature plasmacytoid DC subset (38.7%)
(Fig. 1D, middle panel) and the myeloid DC subset (68.9%)
(Fig. 1E, middle panel). Neither population of DCs expressed sur-
face CD83, as was evident by a lack of staining with the biotinylated
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FIGURE 1. Cell surface binding of sCD83 protein.
sCD83 protein was added to PBMCs, and binding to
CD14+ monocytes or CD19+ B cells was detected using a
secondary goat anti-human CD83 biotinylated Ab, fol-
lowed by allophycocyanin-streptavidin. Gating of viable
monocytes and background staining when cells are
stained with biotinylated anti-CD83 Ab plus allophyco-
cyanin-streptavidin is shown in Supplemental Fig. 1. (Ai)
Viable monocytes and lymphocytes were identified by
side scatter (SSC-H) and forward scatter (FSC-H) gating.
CD14+ cells, representative of monocytes or CD19+ B
cells, and CD142/CD192 cells were identified in the
lymphocyte gate (ii) and monocyte gates (iii). Percent-
ages of CD19+ cells in the lymphocyte gate (iv), CD14+
cells within the monocyte gate (v), and CD142/CD192
cells in the lymphocyte gate (vi) binding sCD83 protein
(open graphs). Background cell staining is shown with
anti-CD83 biotinylated Ab, followed by allophycocya-
nin-streptavidin in the absence of sCD83 protein (shaded
graphs). (B) Cells present in the monocyte gate were
double stained with both Alexa Fluor 488–conjugated
sCD83 protein and the unlabeled protein detected
with the anti-CD83 Ab, followed by allophycocyanin-
streptavidin. (C) To generate a competition binding curve,
cells were incubated with various concentrations (0.25 to
4 mg) of unconjugated sCD83 protein for 15 min at room
temperature. After incubation, Alexa Fluor 488–labeled
sCD83 was added to the cell suspension without prior
washing. The percentage of Alexa Fluor 488–labeled
sCD83 binding is shown in the presence of various
concentrations of unlabeled sCD83. Data are represen-
tative of two to five independent experiments. (D) Plas-
macytoid DCs present in the monocyte gate from a single
donor were identified by expression of CD123 and
CD303 (top panel). Binding of sCD83 protein to CD14+
DCs within the CD123+/CD303+ plasmacytoid DC sub-
set was detected using the same two-step method of in-
cubating sCD83 protein with cells then detection with
anti-CD83 biotinylated Ab followed by allophycocyanin-
streptavidin (middle panel). Background staining in the
absence of sCD83 protein but in the presence of the anti-
CD83 Ab alone, followed by allophycocyanin-streptavidin
(bottom panel). (E) Myeloid DCs present in the monocyte
gate from a single donor identified by expression of
CD1c and CD2 (top panel). Binding of sCD83 protein
to CD14+ DCs within the CD1c+/CD2+ myeloid DC
subset was detected as described above using the indirect
detection method (middle panel). Background staining in
the absence of sCD83 protein (bottom panel).
The Journal of Immunology 2289
 by guest on N
ovem
ber 21, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
FIGURE 2. sCD83 binds to monocytes expressing CD14/TLR4/MD-2 CD44 coreceptors. sCD83 protein was added to PBMC cultures and detection of
surface-bound sCD83 was performed as described in Materials and Methods, in combination with staining for expression of CD14, TLR4, CD44v6, and
MD-2. (A) Representative dot plots showing probability binning to partition data for x2 testing based on positive surface binding with CD83 protein in
combination with CD14 (Ai), TLR4 (Aii), CD44v6 (Aiii), or MD-2 (Aiv) staining. (The gating strategy is shown in Supplemental Fig. 1.) In (Ai), the blue
dots represent CD14+ staining in the absence of sCD83 protein, green dots represent cells binding sCD83 protein in the absence of CD14 staining, and the
red dots represent cells staining double positive for CD14 and sCD83 binding. In (Aii), the blue dots represent TLR4+ staining in the absence of sCD83
protein, green dots represent cells binding sCD83 protein in the absence of TLR4 staining, and the red dots represent the percentage of cells staining double
positive for TLR4 and sCD83 binding. In (Aiii), the blue dots represent CD44v6+ staining in the absence of sCD83 protein, green dots represent cells
binding sCD83 protein in the absence of CD44v6 staining, and the red dots represent the percentage of cells staining double positive for CD44v6 and
sCD83 binding. In (Aiv), the blue dots represent MD-2+ staining in the absence of sCD83 protein, green dots represent cells binding sCD83 protein in the
absence of MD-2 staining, and the red dots represent the percentage of cells staining double positive for MD-2 and sCD83 binding. (B) Box-and-whisker
plots show the distribution of the percentage of cells in the monocyte gate binding sCD83 protein into the upper and lower quartiles (n = 6) (left panel). The
distribution of cells within the monocyte gate that are double positive for sCD83 and CD14 (blue bar), sCD83 and CD44v6 (red bar), sCD83 and TLR4
(green bar), and sCD83 and MD-2 (purple bar) is shown. The level of sCD83 binding, represented by the MFI value, is shown (Figure legend continues)
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anti-CD83 Ab (Fig. 1D, 1E, bottom panels). Both CD14+ DC subsets
are present in the monocyte gate and represent a small, but detect-
able, population of cells with the ability to bind sCD83. In the
monocyte gate, 0.13 and 0.84% of cells consisted of sCD83 bound to
CD14+ plasmacytoid and monocytic DCs, respectively. To extend
these observations, we characterized the phenotype of monocytes
binding sCD83. Fig. 2A shows representative data from one of six
donors: 70.4% of the CD14+ monocyte population (Fig. 2Ai), 74.4%
for cells multistained for TLR4 and MD-2 (middle panel). The blue bar represents the background MFI value of sCD83 detection when cells are multistained
with Abs to detect TLR4 and MD-2 expression without added sCD83 protein (anti-CD83 second step alone). The red bar represents the MFI value of sCD83
binding when cells are double stained to detect MD-2 expression and sCD83 binding. The green bar represents theMFI value of sCD83 binding when cells are
double stained to detect TLR4 expression and sCD83 binding. The purple bar represents the MFI values of sCD83 binding when cells are multistained for
TLR4 and MD-2 expression in the presence of sCD83 binding. The level of sCD83 binding, represented by the MFI value, is shown for cells multistained for
CD14 and CD44v6 (right panel). The blue bar represents the background MFI value of sCD83 detection when cells are multistained with Abs to detect CD14
and CD44v6 expression without added sCD83 protein (anti-CD83 second step alone). The red bar represents the MFI value of sCD83 binding when cells are
double stained to detect CD44v6 expression and sCD83 binding. The green bar represents the MFI values of sCD83 binding when cells are double stained to
detect CD14 expression and sCD83 binding. The purple bar represents the MFI values of sCD83 binding when cells are multistained for CD14 and CD44v6
expression in the presence of sCD83 binding. (Ci) sCD83 binding MFI values plotted versus the CD14 MFI values of cells double positive for sCD83
binding and CD14 expression. (Cii) sCD83 binding MFI values plotted versus the TRL4 MFI values of cells double positive for sCD83 binding and TLR4
expression. (Ciii) sCD83 binding MFI values plotted versus the CD44v6 MFI values of cells double positive for sCD83 binding and CD44v6 expression.
(Civ) sCD83 binding MFI values plotted versus the MD-2 MFI values of cells double positive for sCD83 binding and MD-2 expression. Data shown are
representative of three independent experiments, and each data point is representative of the average of triplicates for each of six donors from one ex-
periment. Statistics are displayed by Spearman rho plots.
FIGURE 3. GM-CSF enhances sCD83 binding to
monocytes expressing high levels of CD44v6. (A)
sCD83 protein binding to monocytes was determined,
as described in Materials and Methods, on untreated
cells (left panel) or GM-CSF–treated cells (right panel).
(B) Expression of CD44v6 was determined on un-
treated cells (left panel) or GM-CSF–treated cells (right
panel). (C) MD-2 expression was determined on un-
treated cells (left panel) or GM-CSF–treated cells
(right panel). Data shown are representative of three
experiments.
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of TRL4+ cells (Fig. 2Aii), 35.5% of CD44v6+ cells (Fig. 2Aiii), and
50.3% of MD-2+ cells (Fig. 1Aiv) bound sCD83. Compiled data
from the six donors showed that 47–75% of CD14+ cells, 20–48% of
CD44v6+ cells, 50–62% of TLR4+ cells, and 11–75% of MD-2+
cells (Fig. 2B, left panel) bound sCD83. Interestingly, when we in-
vestigated the relative level of sCD83 binding by measuring the MFI
values of bound sCD83 protein in combination with Ab staining to
TLR4 and MD-2, there was a nonsignificant, but trending, decrease
in the MFI values of bound sCD83 (Fig. 2B, middle panel, purple
bars). A similar pattern of decreased binding of sCD83 protein in
combination with Ab staining to CD14 and CD44v6 was observed
(Fig. 2B, right panel, purple bars). This prompted us to investigate
the relationship between the level of expression of CD14, TLR4,
MD-2, or CD44v6 and the level of sCD83 protein bound to the cell
FIGURE 4. Blocking sCD83
binding in the presence of Abs to
CD14, MD-2, TLR4, and CD44. (A)
sCD83 binding was determined on
CD14+ monocytes, as described in
Materials and Methods, in the pres-
ence of two isotype-control IgG Abs
(middle and right panels). Back-
ground staining with the anti-CD83
Ab in the absence of sCD83 protein
on CD14+ monocytes (left panel).
CD14 surface expression was mea-
sured using FITC-conjugated anti-
CD14 Ab (clone MY4) that was
added postwashing to blocked sam-
ples. (B) Anti-CD14 Ab clones
M5E2 (left panel), My4 (middle
panel), and 61D3 (right panel) were
incubated with PBMCs prior to the
addition of sCD83 protein, and
sCD83 binding was measured on
CD14+ monocytes stained with
FITC–anti-CD14 Ab. (C) Anti–MD-2
Ab clones 9B4 (left panel) and
288307 (middle panel) and anti–
TLR4/MD-2 Ab clone MTS510
(right panel) were incubated with
PBMCs prior to the addition of
sCD83 protein, and sCD83 binding
was measured on CD14+ monocytes
stained with FITC–anti-CD14 Ab.
(D) Anti-CD44s Ab clones 515 (left
panel), 15363C11 (middle panel),
and 5F12 (right panel) were incu-
bated with PBMCs prior to the ad-
dition of sCD83 protein, and sCD83
binding was measured on CD14+
monocytes stained with FITC–anti-
CD14 Ab. Data shown are repre-
sentative of three experiments.
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surface (Fig. 2C). By plotting the MFI values for bound sCD83
protein versus the MFI values of CD14, TLR4, CD44v6, or MD-2
surface expression, a statistically significant correlation was noted
between the MFI values of bound sCD83 and cell surface expression
of CD44v6 (Fig. 2Ciii) and MD-2 (Fig. 2Civ). No correlation was
found between the MFI of bound sCD83 and MFI values for surface
expression of CD14 (Fig. 2Ci) or TLR4 (Fig. 2Cii). Further binding
analysis using PBMCs from a donor whose monocytes bound low
levels of sCD83 (15.6%, Fig. 3A, left panel) showed that, if PBMCs
were first treated with GM-CSF overnight, there was an increase in
sCD83 binding (69.4%, Fig. 3A, right panel); a concurrent upregu-
lation of CD44v6 expression from 39.6% (Fig. 3B, left panel) to
83.8% (Fig. 3B, right panel) was observed, and there was little
change in MD-2 expression (Fig. 3C).
CD44 containing the v6 variant is essential for sCD83 binding
Given the observation that sCD83-binding cells are CD14, MD-2,
TLR4, and CD44v6 positive, and all four molecules associate with
the TLR4 heterodimer (37), we investigated which molecules in
the TLR4/MD-2/CD14–CD44 complex were necessary or essen-
tial for the binding of sCD83 to the surface of monocytes. Ab-
blocking experiments were used to determine which molecules are
required for sCD83 binding to the cell surface of monocytes.
sCD83 bound to 47.8 and 60% of CD14+ monocytes in the
presence of two isotype-control Abs (Fig. 4A, middle and right
panels). Background staining in the absence of sCD83 protein is
shown (Fig. 4A, left panel). Preincubation of monocytes with anti-
CD14 Ab clone M5E2 reduced sCD83 binding to 27.6% (Fig. 4B,
left panel), and clones My4 and 61D3 reduced sCD83 binding to
8.3% (Fig. 4B, middle panel) and 5.9% (Fig. 4, right panel), re-
spectively. Interestingly, all three Ab clones can detect surface
expression of CD14, but clone M5E2 reportedly is unable to block
LPS-induced activation of monocytes (56). Because this clone
showed less of a reduction in sCD83 binding, it suggests that
sCD83 interacts with a region associated with LPS binding. We
next evaluated the ability of anti–MD-2 Abs to reduce sCD83
surface binding (Fig. 4C). Only one of the two MD-2–specific Abs
tested (clone 288307) partially reduced sCD83 binding to 49.2%
(Fig. 4C, middle panel) versus 63% for clone 9B4 (Fig. 4C, left
panel). Furthermore, the Ab clone MTS510, with specificity for
the complexed TLR4/MD-2 molecules, did not reduce CD83
binding (64.7%) (Fig. 4C, right panel). Next, we investigated the
contribution of CD44R to the ability of cells to bind sCD83 be-
cause CD44 was reported to associate with the TLR4 complex
(47). As other investigators reported, CD44 recognition of hya-
luronan regulates TLR4 inflammatory signals during acute pul-
monary inflammation (44). These data, taken together with our
preliminary observation that expression of CD44v6 is associated
with sCD83 binding, led us to investigate the binding of sCD83 in
the presence of Abs that target the standard extracellular region of
CD44 (Fig. 4D). All three anti-CD44 Ab clones with specificity
for the standard extracellular region of CD44 completely reduced
sCD83 binding to the surface of monocytes, with residual sCD83
binding of 3–5% (Fig. 4D). In a separate experiment, sCD83
bound to 86.9% of CD14+ cells (Fig. 5A, first panel), and anti-
CD44 Ab reduced the binding to 10% of cells (Fig. 5A, second
panel). However, if sCD83 protein was premixed with soluble
recombinant MD-2 protein prior to the addition to cells, pre-
sumably to allow the sCD83/MD-2 complex to form, cell surface
binding was partially restored from 10% (Fig. 5A, second panel)
to 55.5% (Fig. 5A, fourth panel) in the presence of anti-CD44
blocking Ab. In the absence of anti-CD44 Ab, preincubation of
sCD83 and MD-2 protein did not alter sCD83 cell surface binding
(Fig. 5A, third panel). Additionally, if an Ab with specificity for
the CD44v6 region, which recognizes an epitope along the stem
region of the receptor, is added prior to the addition of sCD83
protein, no reduction in sCD83-bound protein is observed. The
percentage of bound sCD83 protein was 93% in the absence of
anti-CD44v6 Ab (Fig. 5B, open graph) and 89% in the presence of
Ab (Fig 5B, shaded graph). Because all CD44Rs express the
standard extracellular region but exhibit variation with regard to
the variant regions present in the stem loop, we conclude that the
extracellular domain of CD44 is necessary for sCD83 binding, and
expression of at least the variant 6 region is required to facilitate
sCD83 binding. Furthermore, increased abundance of MD-2
protein can overcome anti-CD44 Ab inhibition of sCD83 binding.
sCD83 binds to MD-2 with high affinity
Given the observation that the binding of sCD83 to monocytes was
blocked with Abs to CD14 or CD44, and the addition of soluble
MD-2 mediates CD44-independent sCD83 binding to the cell
surface of monocytes, it was of interest to determine the binding
affinities between sCD83 and the coreceptors CD14, CD44, and
MD-2. To quantitate the binding of sCD83 to MD-2, CD44, and
CD14, a cell-free ELISA-based assay was developed. Increasing
concentrations of recombinant MD-2, CD44s, or CD14 protein
were added to immobilized sCD83 protein, and the binding af-
finities were determined. MD-2 protein bound to sCD83 with a kDa
of 7.2 nM; however, neither CD14 nor CD44s bound to sCD83
protein with a measurable affinity (Fig. 6A). The fact that the
FIGURE 5. MD-2 enhances sCD83 binding to monocytes. (A) Percentage of bound sCD83 protein to CD14+ cells in the absence of anti-CD44s (standard
form) Ab and MD-2 protein (first panel). The percentage of sCD83 protein binding was determined in the presence of anti-CD44s Ab (clone IM-7, second
panel) or with anti-CD44s Ab + soluble MD-2 protein (fourth panel). Cells were incubated with anti-CD44 Ab and then with sCD83 and MD-2 proteins
premixed prior to addition to cells. The percentage of sCD83 binding in the presence of MD-2 protein without anti-CD44s Ab is shown (third panel). (B)
sCD83 binding (shaded graph) on the cell surface in the presence of anti-CD44v6 Ab (clone VFF-7) or in the absence of anti-CD44v6 Ab (open graph). The
filled graph shows staining with anti-CD83 Ab in the absence of sCD83 protein. Data shown are representative of two independent experiments.
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binding assay with CD44s or CD14 protein did not yield a satu-
ration curve suggests that sCD83 does not bind directly to CD44s
or CD14. The crystal structure of agonist and antagonist ligands
binding to the TLR4/MD-2 complex was determined (31). LPS-
derived antagonists were tested as potential therapeutic candidates
to treat sepsis by preventing signaling through the TLR4/MD-2
coreceptors (38). Therefore, it was of interest to test the ability of
MD-2 protein to bind immobilized sCD83 protein in the presence
of exogenous LPS or LPS derivatives KDO–lipid A, mono-
phosphoryl–lipid A, and diphosphoryl–lipid A to map the sCD83
binding site on MD-2. Recombinant MD-2 protein was incubated
with each of these LPS derivatives prior to addition to plates
coated with sCD83 protein (Fig. 6B); if MD-2 bound to LPS, or
the LPS derivatives blocked sCD83 binding, the interaction of
sCD83 with MD-2 may mimic antagonist regulation of TLR
signaling. Only the KDO–lipid A variant (n) preincubated with
MD-2 prevented MD-2 binding to sCD83 (Fig. 6B). Neither Lipid
A derivative containing one or two phosphate groups nor LPS
preincubated with MD-2 protein blocked MD-2 binding to sCD83.
However, if the KDO–lipid A variant was added to sCD83-bound
plates and washed prior to the addition of MD-2 protein (N), it no
longer blocked MD-2 binding to sCD83. This suggests that sCD83
does not directly bind LPS, and LPS preformed with MD-2 pre-
vents sCD83 interaction with the TLR4/MD-2 complex. These
data imply that sCD83 binds to MD-2 at a site close to the in-
teraction of the KDO portion of the lipid molecule but distal to the
lipid A tail. Moreover, the ability of anti-CD44s and anti-CD14
Abs to block sCD83 cell surface binding is related to the close
proximity of these receptors to TLR4. MD-2 binding to sCD83 is
reminiscent of its role in the transfer of LPS from CD14R to TLR4
leading to conformational changes and the initiation of signaling
events. Taken together, these data indicate that the complex
formed between MD-2 and sCD83 is stable, and MD-2 is the
dominant high-affinity binding partner for sCD83.
sCD83 binding alters the TLR4/MD-2 signaling cascade at the
level of IRAK-1 protein expression
Modulation of IRAKs is pivotal in regulating signals through the
TLR4 complex (50, 57). Specifically, IRAK-1 is involved in the
early signaling cascade downstream of MyD88, leading to in-
duction of NF-kB and cytokine gene transcription (40). Interest-
ingly, it was reported that CD44 can regulate TLR signaling by
inducing the negative IRAK regulator IRAK-M (48), and tumor-
derived hyaluronan interacts with CD44 and inhibits IRAK-1
expression in monocytes, leading to increases in IL-10 (58).
Therefore, it was of interest to test the hypothesis that sCD83
signals through TLR4 and alters this cascade. We investigated the
expression of IRAK proteins in the presence of sCD83 by puri-
fying monocytes by negative selection and culturing them over-
night in medium containing GM-CSF to induce expression of
IRAK-1 protein, because freshly isolated monocytes do not ex-
press IRAK-1 protein, even when cultured in medium alone (data
not shown). GM-CSF–cultured monocytes were incubated with
sCD83 or LPS and assayed for the presence of IRAK-1, IRAK-2,
IRAK-M, and IRAK-4 proteins (Fig. 7). IRAK-1 protein was
detected in untreated cultures and LPS-treated cultures in contrast
to cultures treated with sCD83 (Fig. 7A). Furthermore, no change
in IRAK-2, IRAK-4, and IRAK-M protein levels was detected
when cells were treated with sCD83 for 60 min (Fig. 7A). Given
the loss of IRAK-1 protein expression within 60 min of treating
cells with sCD83, we assessed IRAK-1 expression at earlier and
later time points. IRAK-1 protein expression was lost rapidly by
10–15 min after sCD83 addition, in contrast to stimulation with
LPS (Fig. 7B). This lack of IRAK-1 protein was sustained out past
2–3 d (Fig. 7C), and no evidence of protein restoration could be
detected out to 7 d post-sCD83 addition (Fig. 7C, 7D). As shown
with the early time course, no loss of IRAK-2, IRAK-M, or IRAK-4
was seen at 2–3 and 7 d post-sCD83 treatment (Fig. 7C, 7D).
Interestingly, we did not detect any impact on downstream TRAF6
protein levels during the time course of IRAK-1 loss at 30 min or
out to 6 and 24 h post-sCD83 treatment (Fig. 7E).
sCD83 suppresses T cell proliferation and induces IL-2
unresponsiveness
We next tested the functional immune-modulatory impact that
sCD83 has on T cell proliferation. sCD83 was added to anti-CD3/
anti-CD28–stimulated PBMCs containing monocytes. The addi-
tion of soluble T cell–specific stimulatory Abs allows APCs pre-
sent in T cell cultures to cross-link TCRs and costimulatory
FIGURE 6. sCD83 binds to MD-2 with high affinity near the KDO–lipid
A binding site on TLR4/MD-2. (A) Recombinant MD-2, CD14, or CD44
proteins were added to sCD83-coated plates at the indicated concentra-
tions, and bound protein was detected using biotin-conjugated Abs to
MD-2, CD14, or CD44, respectively. Nonspecific binding determined us-
ing plates not coated with sCD83 was subtracted from specific binding
detection. (B) MD-2 protein (0.25 mg/ml) was coincubated with serial
dilutions of LPS, KDO–lipid A, lipid A diphosphate, or lipid A mono-
phosphate prior to addition to sCD83-coated plates. Alternatively, serial
dilutions of KDO–lipid A were added to the sCD83-coated plates, and
plates were washed prior to the addition of MD-2 protein. Biotinylated
anti–MD-2 Ab was used to detect MD-2 protein bound to immobilized
sCD83. Binding affinity for MD-2 was calculated using five-parameter
logistic curve fitting within SigmaPlot software. Data shown are repre-
sentative of two independent experiments.
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molecules on the T cell, leading to T cell activation and prolif-
eration. CFSE-labeled PBMCs from normal donors were stimu-
lated in the presence of sCD83 for 6 d, and the percentage of
proliferating CD4+ T cells and CD8+ T cells was measured by
CFSE dilution. Representative dot plots show that sCD83 de-
creased the percentage of CD4+ T cell proliferation (Fig. 8A,
upper panels) and CD8+ T cell proliferation (Fig. 8A, lower
panels). Across a cohort of five donors tested, addition of sCD83
caused a statistically significant decrease in CD4 T cell prolifer-
ation (from 89 to 25%) and CD8 T cell proliferation (from 87 to
38%) (Fig. 8B). This prompted us to quantitate the absolute
numbers of proliferating CD4+ and CD8+ T cells in the cultures
treated with sCD83. sCD83 suppression of T cell proliferation was
dose dependent; cultures treated with sCD83 had fewer total
numbers of proliferating CD4+ and CD8+ T cells than did the
untreated cultures (Fig. 8C). To assess the expansion of sCD83-
treated CD4+ and CD8+ T cells upon secondary stimulation, IL-2
was added to previously stimulated cultures on day 8. Two days
later, proliferation was measured by CFSE dilution over multiple
cell divisions; zero cell divisions represents nonproliferating cells,
and the number of proliferating CD4+ or CD8+ T cells per mil-
liliter was determined for each subsequent cell division. CD4+ and
CD8+ T cells stimulated previously in the presence of sCD83 were
unable to respond to IL-2 addition compared with T cells stimu-
lated previously in the absence of sCD83 (Fig. 8D). This suggests
that sCD83 inhibits T cell proliferation when APCs are present
and renders T cells unresponsive to further stimulation with IL-2.
Given that sCD83 binds to the MD-2 coreceptor of the TLR4
complex expressed on monocytes, and sCD83 addition to T cell
cultures containing monocytes results in suppression of T cell
proliferation, it was of interest to see whether LPS or KDO–
lipid Awould have a similar effect, because these molecules signal
through TLR4 and may block T cell activation. Furthermore,
recombinant sCD83 protein was derived from bacterial sources
and could contain low levels of bacterial components, such as
LPS, which could modulate T cell activation. T cell proliferation
was determined in the presence of 50 mg/ml sCD83 or a combi-
nation of 100 ng/ml LPS and KDO–lipid A. Although sCD83
suppressed CD4+ and CD8+ T cell proliferation, the combination
of LPS and KDO–lipid A did not block CD4+ (Fig. 8E) or CD8+
(Fig. 8F) T cell proliferation. Therefore, sCD83 inhibition of
T cell proliferation functions through a different mechanism
FIGURE 7. sCD83 signals through the TLR4/MD-2 coreceptor by downregulating IRAK-1 expression. Purified monocytes were cultured overnight in
medium containing GM-CSF and then stimulated with 25 mg/ml sCD83 protein or 100 ng/ml LPS for 60 min (A), 10, 15, or 30 min (B), 24, 48, or 72 h (C),
6, 24, or 48 h and 7 d (D), or 30 min or 2 or 6 h (E). Cell lysates were prepared, and equivalent cellular protein concentrations were Western blotted with
Abs to IRAK-1, IRAK-2, IRAK-M, IRAK-4, and TRAF6 or with b-actin as a loading control. Data shown are representative of three independent
experiments.
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than LPS signaling, and sCD83 inhibition is independent of LPS
contaminants.
sCD83 mechanism of action is mediated through COX-2 and
IL-10 pathways, a potential role for IDO
Previous investigations of sCD83 preparations used to suppress
T cell proliferation revealed that PGE2, through COX-2 activation,
was responsible for the ability of sCD83 to block T cell prolif-
eration (28). We confirm those findings in this study and provide
new evidence for a role for IL-10 and IDO in sCD83-dependent
suppression of T cell cytokine secretion. sCD83 treatment resulted
in suppression of IL-2 (Fig. 9A), IFN-g (Fig. 9B), IL-5 (Fig. 9C),
and IL-13 (Fig. 9D) secretion in stimulated cultures. Concurrently,
there was an induction of IL-6 (Fig. 9E), IL-10 (Fig. 9F), and
FIGURE 8. sCD83 blocks T cell proliferation and renders T cells unresponsive to IL-2. CFSE-labeled PBMCs were stimulated with anti-CD3 and anti-
CD28 Abs for 6 d, with or without the addition of sCD83 protein. Proliferation was measured by CFSE dilution by flow cytometry. (A) Dot plots show the
inhibition of proliferation by sCD83. The CFSElow gate shows CD4+ or CD8+ T cells that proliferated in the presence or absence of sCD83 protein, whereas
the CFSEhigh gate shows nonproliferating cells. (B) Whisker plots showing the range of inhibition of sCD83 for five individual donors. Each point represents
one donor. Cells were treated or not with sCD83, and the percentage of proliferation was measured on day 6 in untreated CD4+ T cells (d), sCD83-treated
CD4+ T cells (s), untreated CD8+ T cells (▴), and sCD83-treated CD8+ T cells (O). (C) Cells were treated with 0, 2, 10, or 50 mg/ml sCD83, and the total
number of proliferating CD4+ T cells and CD8+ T cells was calculated. (D) Eight days post–T cell stimulation, 20 U/ml IL-2 was added to PBMC cultures
previously stimulated with anti-CD3/anti-CD28 Abs in the presence (s, N) or absence (d, n) of sCD83 protein. Proliferation by CFSE dilution was de-
termined 3 d later by measuring the number of CD4+ T cells (s, d) and CD8+ T cells (N, n) proliferating within each division. CFSE-treated human PBMCs
were stimulated to proliferate with anti-CD3 and anti-CD28 Abs in the absence (¤) or presence of 50 mg/ml sCD83 (n) or 100 ng/ml LPS+KDO (▴), and
the number of CD4+ T cells (E) or CD8+ T cells (F) proliferating within each division was determined 6 d later. All data points were run as replicates; error
bars represent the range of each individual data point. Data sets are representative of two to five experiments from up to five individual donors. **p , 0.01.
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FIGURE 9. sCD83 modulates cytokine and PGE2 secretion and induces IDO activity. Culture supernatant was collected 24 h (IL-2, IFN-g, IL-6,
IL-10, and PGE2) or 4 d (IL-5 and IL-13) after PBMCs were stimulated with anti-CD3 and anti-CD28 Abs in the presence of sCD83 alone or in
combination with anti–IL-10 Ab or the COX-2 inhibitor NS-398. Cytokine concentrations were determined by cytokine bead arrays for IL-2 (A),
IFN-g (B), IL-5 (C), IL-13 (D), IL-6 (E), and IL-10 (F). (G) PGE2 concentration was determined using a competitive ELISA. (H) IDO activity was
measured in 24-h culture supernatant from PBMCs that were stimulated to proliferate with anti-CD3 and anti-CD28 Abs. Some cultures were left
untreated or were treated with 50 mg/ml sCD83 in combination with anti–IL-10 Ab or COX-2 inhibitor. Error bars represent SD of cytokine bead
array data sets. Data sets are representative of two to four experiments. Open bars, normal donor 1; closed bars, normal donor 2. Statistics shown
above horizontal lines represent comparison of untreated samples with sCD83-treated samples. Statistics shown above individual bars represent
comparison of sCD83-treated sample with samples treated in combination with anti–IL-10 Ab or the COX-2 inhibitor for each donor. *p , 0.05,
**p , 0.01.
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PGE2 (Fig. 9G). Partial reversal of sCD83-dependent inhibition of
IFN-g is dependent on neutralization of IL-10 (Fig. 9B), and
blocking PGE2 secretion with a COX-2 inhibitor partially restored
IL-5 (Fig. 9C) and IL-13 (Fig. 9D) in both donors tested. The
COX-2 inhibitor blocked PGE2 production (Fig. 9G), as previ-
ously reported (28), and, in our experiments, the COX-2 inhibitor
partially suppressed sCD83-induced IL-10 secretion (Fig. 9F),
with minimal effect on IL-6 (Fig. 9E). The predominant cell type
secreting IL-10 in the sCD83-treated cultures was CD14+ mono-
cytes, with a small contribution by CD4+ T cells. No difference in
IL-10 secretion by CD8+ T cells and CD19+ B cells was detected
(Fig. 10A). Furthermore, inhibition of IFN-g secretion by CD8+
T cells and CD14+ monocytes in the cultures is more sensitive to
sCD83 than is that by CD4+ T cells (Fig. 10B). Interestingly, we
observed a strong induction of TNF-a by CD14+ monocytes in the
sCD83-treated cultures, with no impact on TNF-a secretion by
CD4+ T cells and a decrease in TNF-a secretion by CD8+ T cells
(Fig. 10C). These data suggest differential regulation of these
cytokines post–TLR4/MD-2 engagement with sCD83. It was
reported that IL-10 secretion can be upregulated in a COX-2–
dependent manner through feedback regulation of PGE2 (59, 60).
This positions PGE2 upstream in the sCD83 signaling cascade of
anti-inflammatory modulators leading to IL-10 induction. Inter-
estingly, we observed inhibition of IFN-g secretion that prompted
us to investigate a link between IDO activity and IFN-g (61, 62).
We measured IDO enzyme activity in PBMC cultures stimulated
in the presence of sCD83. IDO activity was increased in sCD83-
treated cultures, shown as an increase in the kynurenine/
tryptophan ratio (Fig. 9H). However, this increase was not sta-
tistically significant. Regardless, this induction of IDO activity
could be partially blocked in the presence of the COX-2 inhibitor
(Fig. 9H), whereas blocking IL-10 had little or no effect. There-
fore, sCD83-induced suppression of T cell cytokine profiles is
mediated through the TLR4/MD-2 coreceptor, and it results in the
induction of a combination of PGE2, IDO, IL-10, and TNF-a.
These data are consistent with our previous observation that
sCD83-mediated corneal allograft survival and long-term kidney
allograft survival were abolished in the presence of the IDO-
specific inhibitor 1 methyl-tryptophan (20, 27).
Discussion
CD83 plays a central role in regulating the immune system and is
a prime target for therapeutic intervention. Various preparations of
recombinant sCD83 were reported to modulate immune responses;
however, until now, the sCD83 receptor/ligand on the appropriate
target cell has not been identified. Recently, it was suggested that
CD83 may act in a homotypic way (30); however, the investigators
failed to demonstrate a clear biophysical interaction and, there-
fore, the exact receptor for sCD83 on cells has yet to be deter-
mined. Other investigators showed that sCD83 binds to human
monocytes (28). We confirmed the binding of sCD83 to mono-
cytes in this study and extended the APC types binding sCD83 to
include CD14+ plasmacytoid and myeloid DC subsets present in
peripheral blood. The presence of CD14+ blood DCs was origi-
nally reported and shown to identify a precursor DC population
that was capable of stimulating T cell responses (63). This raises
the possibility that binding of sCD83 to CD14+ blood DCs may
influence DC maturation and impact T cell stimulation. Further-
more, we identified a small population of CD19+/CD142 B cells
that bound sCD83 protein. More importantly, we provide, for the
first time to our knowledge, direct evidence that sCD83 binds to
the MD-2 molecule, the coreceptor for TLR4 expressed on human
monocytes. Identification of the MD-2 coreceptor as the high-
affinity binding partner for sCD83 allowed us to map early sig-
nals delivered through sCD83 engagement of TLR4/MD-2 that
result in secretion of PGE2, IL-10. These anti-inflammatory me-
diators are responsible for the ability of sCD83 to block T cell
activation and contribute to the overall suppression of proliferation
and secretion of IL-2, IL-5, IL-13, and INF-g. Moreover, prior
exposure to sCD83 induces a state of T cell anergy that is defined
by a lack of subsequent proliferation upon exposure to IL-2.
Our initial characterization of sCD83 binding to monocytes
revealed a contribution of other coreceptors that are involved in
coordinating TLR4 signaling. Abs directed to CD14 and the
standard extracellular domain of CD44 expressed on all variants
blocked sCD83 binding, revealing a close proximity of CD14 and
CD44 with the sCD83-TLR4/MD-2 receptor complex. However,
neither the recombinant CD14 nor CD44s protein bound with high
affinity to sCD83 under cell-free conditions that facilitate direct
protein–protein interactions, but sCD83 bound with high affinity
to recombinant MD-2 protein under the same conditions. There-
fore, the docking protein within the CD14/TLR4/MD-2–CD44v6
complex is the MD-2 molecule. CD44s containing the standard
extracellular domain can be expressed on the cell surface in
multiple forms, depending on the expression of variant regions of
the stem region (v1–v10) (49). During our screening for sCD83
binding to monocytes, we discovered that the level of MD-2 and
FIGURE 10. sCD83 induces IL-10 and TNF-a secretion from mono-
cytes. Normal human PBMCs were stimulated with anti-CD3 and anti-
CD28 Abs and treated or not with sCD83 for 24 h. Intracellular cytokine
expression was measured by flow cytometry. (A) IL-10. (B) IFN-g. (C)
TNF-a. Data are representative of two normal donors and two separate
experiments. *p , 0.05, **p , 0.01.
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CD44v6 surface expression can vary and impact the binding of
sCD83 protein. By comparing the cell surface expression level of
MD-2 or CD44v6 with the relative amounts of sCD83 bound to
the cell surface, a correlation was observed that linked the ex-
pression levels of MD-2 or CD44v6 with sCD83 surface binding.
Furthermore, if sCD83 binding was low, higher levels of binding
could be restored if monocytes were stimulated with GM-CSF to
upregulate CD44v6 protein expression. Moreover, if MD-2 protein
was first bound to sCD83 in solution, sCD83 binding could be
restored in the presence of Abs to CD44 that normally block
sCD83 binding, suggesting that MD-2 tethers sCD83 into the
TLR4 complex, and CD44 is in close proximity to the complex.
Because we could not show a direct protein–protein interaction
between CD44s and sCD83, but Abs directed to the CD44s portion
of CD44R blocked binding, we propose a model (Fig. 11) whereby
sCD83 binding to monocytes is dependent on the expression of the
CD44v6 variant that expresses the standard extracellular domain
with at least the v6 variant of the stem loop region. The CD44v6
form of CD44 facilitates the conformation necessary to allow
sCD83 to bind to MD-2 within the complex. The normal function of
MD-2 is to tether LPS to TLR4, which leads to potent proin-
flammatory signals through heterodimerization of the receptor (31).
Ligand engagement of TLR4/MD-2 dimers induces a signaling
cascade downstream of MyD88 activation involving the phosphor-
ylation of the adaptor protein IRAK-1 via IRAK-4. Activated
IRAK-1 tethers to TRAF6 and leads to the nuclear translocation of
NF-kB, inducing a proinflammatory cytokine cascade (40, 64, 65).
Downstream regulation of TLR4 signaling occurs at several
checkpoints to modulate excessive inflammation, especially
during resolution of inflammation (40, 41). Downregulation of
IRAK-1 protein was reported in models of LPS tolerance (57),
and loss of IRAK-1 is reported in tolerogenic DCs (66). The
concept of antagonist ligands modulating TLR4 function was
investigated in models of autoimmune arthritis (67), myocardial
ischemia (68), and endotoxin-induced uveitis (69). Spontaneous
models of colitis in mice using TLR4 knockouts revealed disease
exacerbation that was dependent on TLR4 signals and IL-10
(70). One such pathway of TLR4 regulation is at a point of in-
duction of IL-10 through a COX-2–dependent mechanism (71).
In this article, we provide evidence, for the first time to our
knowledge, that sCD83 engages the coreceptor MD-2 associated
with TLR4 during early monocyte activation and results in
sustained downregulation of IRAK-1. Whether it is through a
loss of protein expression or protein degradation requires further
studies to elucidate the exact mechanism modulating IRAK-1
levels by sCD83. In our model, a lack of IRAK-1 protein re-
sults in a shift to an anti-inflammatory state characterized by
PGE2 and IL-10 secretion. Additionally, sCD83 was shown to
prevent experimental autoimmune encephalomyelitis (25) and
colitis (26) in murine models, both of which were shown to be
critically dependent on IRAK-1 activity (51, 72). Interestingly,
we saw no evidence for upregulation of IRAK-M, the pseudo-
kinase shown to be a negative regulator of TLR signaling (73).
Although the exact signaling cascade through TLR4 that links
COX-2 activation and IL-10 in our system is under investigation,
other investigators showed a link between IL-10 production and
COX-2 in non-small cell lung carcinoma patients (74). Fur-
thermore, IL-10 was reported to upregulate MD-2 and CD14
(75), which may have the added effect of enhancing the tolero-
genic properties of sCD83 by providing more coreceptors to
interact with sCD83. The addition of a COX-2 inhibitor during
T cell stimulation in the presence of sCD83 resulted in a decrease
in PGE2 and IL-10 secretion, whereas anti–IL-10 neutralizing Abs
do not inhibit PGE2 secretion. Therefore, we place sCD83-induced
IL-10 secretion downstream of COX-2 activity. Upon further in-
vestigation of the sCD83 signaling pathway, we revealed a role for
IDO in this pathway that was also dependent on COX-2. This
suggests that sCD83 signals via tolerogenic pathways and gener-
ates IL-10 secretion and IDO in a COX-2/PGE2–dependent
mechanism. This anti-inflammatory phenotype is similar to what
FIGURE 11. Schematic model depicting the interaction of sCD83 protein with the TLR4/MD-2 complex. TLR4 proinflammatory signals originate after
LPS is bound through the interaction with CD14 and MD-2. MD-2 binding to LPS induces a conformational change in the MD-2/TLR4 heterodimers
allowing the transduction of signals through the IRAK family of tyrosine kinases. sCD83 binds directly to MD-2 within the MD-2/TLR4 complex fa-
cilitated by CD44v6. The results of Ab-blocking experiments provide a role for the association of CD14 and CD44v6 within close proximity to the sCD83
binding site on the TLR4/MD-2 complex. sCD83 binding through TLR4/MD-2 results in a rapid and sustained loss of IRAK-1 leading to an altered
signaling cascade toward an anti-inflammatory response.
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was reported for myeloid-derived suppressor cells (76). We pro-
pose a model whereby sCD83 induces a positive-feedback loop
based on early induction of PGE2 that enhances COX-2 activation,
leading to IL-10 secretion and IDO activity. This is reminiscent of
the functional phenotype of immature DCs that, when exposed to
PGE2 during the early differentiation of DCs, leads to an anti-
inflammatory phenotype expressing IL-10 and IDO (77). The
specific cell type responsible for PGE2 secretion and IDO activity
remains to be determined, and further studies are warranted to help
define their role in sCD83-mediated T cell suppression. Interest-
ingly, we observed enhanced TNF-a secretion by CD14+ mono-
cytes in sCD83-treated cultures, which may have the additive effect
of modulating IDO activity (78). Further investigation of the role of
TNF-a in sCD83-mediated suppression is also warranted. Other
investigators reported secretion of PGE2, but not IL-10, when
PBMCs are stimulated in the presence of a CD83–Ig fusion protein
(28). The differences reported in the cytokine profile may be due to
the differences in the preparations of sCD83. The sCD83–Ig fusion
protein may not bind to the TLR4/MD-2 complex with sufficient
affinity; therefore, it may transmit only a partial signal resulting in
upstream signaling that leads to PGE2 secretion but is insufficient
to induce IL-10. The consequence of IL-10, TNF-a, and PGE2
secretion coupled with IDO activity after sCD83 addition to T cell–
stimulated cultures may lead to a block in T cell proliferation and a
decrease in IL-2 secretion. Furthermore, T cells activated in the
presence of sCD83 are unable to respond to further stimulation
with exogenous IL-2. This is very similar to what is reported when
T cells are stimulated in conditions containing IL-10 (79).
Previous studies showed that a short course of sCD83 ad-
ministered to mice receiving orthotopic kidney allograft trans-
plants resulted in graft survival . 100 d compared with a median
survival of 35 d in untreated animals (19). To further understand
the molecular basis for how sCD83 prevents allograft rejection,
we tested the dependency of sCD83 activity on TLR4 signaling
by using TLR4-deficient mice as kidney donors. Preliminary
results provided evidence that, even with sCD83 administration
to the recipient, the donor organ from TLR4-deficient animals
was rejected at a median of 41.4 d, a similar time frame for
animals not treated with sCD83. Therefore, we propose one
possible mechanism in the transplant model: when sCD83 is
administered to the recipient, the donor organ is no longer sus-
ceptible to the tolerogenic signals provided by sCD83 due to a
lack of TLR4/MD-2. Therefore, there is no localized tolerance
induced by sCD83-mediated secretion of IL-10, TNF-a, and
PGE2 at the organ site. Further experiments are required to
provide definitive proof regarding this mechanism of tolerance.
Therefore, sCD83 induces a state of long-term unresponsiveness
similar to T cell anergy (80). This ability of sCD83 to render Ag-
specific T cells unable to respond to continued stimuli would be
an advantageous therapeutic agent to treat a variety of autoim-
mune diseases and prevent graft rejection.
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